Business Combinations - Narrative (Details) $ in Thousands				1 Months Ended	3 Months Ended	4 Months Ended	12 Months Ended
	Aug. 02, 2021 USD ($) asset shares	Mar. 12, 2021 USD ($)	Dec. 03, 2019 USD ($)	Mar. 31, 2021 USD ($)	Mar. 31, 2021 USD ($)	Jun. 30, 2021 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2019 USD ($)
Business Acquisition [Line Items]
Acquisition related contingent consideration							$ 5,722	$ 7,594
Goodwill							707,904	2,725
Share-based compensation expense							$ 22,519	12,995	$ 9,807
Estimated useful life							10 years 10 months 24 days
Release of valuation allowance							$ (41,900)	(13,400)	(9,900)
Cost of testing revenue
Business Acquisition [Line Items]
Share-based compensation expense							640	369	277
Research and development
Business Acquisition [Line Items]
Share-based compensation expense							4,636	2,690	1,856
Selling and marketing
Business Acquisition [Line Items]
Share-based compensation expense							$ 4,390	3,474	$ 2,938
Decipher product technology
Business Acquisition [Line Items]
Estimated useful life							10 years
Decipher trade names
Business Acquisition [Line Items]
Estimated useful life							5 years
HalioDx developed technology
Business Acquisition [Line Items]
Estimated useful life							10 years
HalioDx customer relationships
Business Acquisition [Line Items]
Estimated useful life							6 years
HalioDx customer backlog
Business Acquisition [Line Items]
Estimated useful life							4 years
HalioDx SAS
Business Acquisition [Line Items]
Equity interest acquired	100.00%
HalioDx Inc.
Business Acquisition [Line Items]
Equity interest acquired	100.00%
HalioDx
Business Acquisition [Line Items]
Considerations paid in acquisition	$ 319,640
Shares issued for purchase consideration for a business combination	$ 147,089
Shares transferred in acquisition (in shares) | shares	3,300,000
Incurred liabilities in acquisition	$ 4,194
Transaction costs							$ 11,500
Acquisition related contingent consideration	$ 16,800
Percentage of cash consideration holdback placed in escrow	50.00%
Required service period associated with cash consideration holdback	2 years
Revenues associated with acquisition							11,500
Operating loss associated with acquisition							(13,000)
Goodwill	$ 248,814
Deferred tax liability	7,409
Cash considerations paid in acquisition	168,357
Right-of-use assets, operating lease	2,136
Fair value of finite-lived intangible assets	$ 60,303
HalioDx | Free Shares
Business Acquisition [Line Items]
Unvested free shares modified (in shares) | shares	11,031
Fair value of free shares modified (in shares)	$ 5,100
Pre-combination services associated with free shares modified	3,500
HalioDx | Employee stock options
Business Acquisition [Line Items]
Pre-combination services associated with options vested	400
Nonrecurring post-combination compensation expense associated nonvested options	1,500
HalioDx | Restricted stock units
Business Acquisition [Line Items]
Fair value of awards granted	$ 16,500
Vesting period of awards granted	4 years
Share-based compensation expense							3,500
HalioDx | Restricted stock units | Non-substantive Employee
Business Acquisition [Line Items]
Share-based compensation expense							2,000
HalioDx | HalioDx developed technology
Business Acquisition [Line Items]
Intangible asset acquired | asset	3
HalioDx | HalioDx customer relationships
Business Acquisition [Line Items]
Intangible asset acquired | asset	2
HalioDx | HalioDx customer backlog
Business Acquisition [Line Items]
Intangible asset acquired | asset	2
HalioDx | Post-Combination Compensation Expense
Business Acquisition [Line Items]
Considerations paid in acquisition							4,500
HalioDx | Post-Combination Compensation Expense | Cost of testing revenue
Business Acquisition [Line Items]
Considerations paid in acquisition							300
HalioDx | Post-Combination Compensation Expense | Research and development
Business Acquisition [Line Items]
Considerations paid in acquisition							800
HalioDx | Post-Combination Compensation Expense | Selling and marketing
Business Acquisition [Line Items]
Considerations paid in acquisition							1,300
Decipher Biosciences
Business Acquisition [Line Items]
Equity interest acquired		100.00%
Considerations paid in acquisition		$ 594,694
Incurred liabilities in acquisition		44,179
Transaction costs							10,600
Goodwill		468,266
Deferred tax liability		4,740
Cash considerations paid in acquisition		550,515				$ 43,800
Acceleration and cash settlement of unvested acquiree employee stock awards					$ 25,100
Net loss							18,200
Total revenues							65,900
Increase (decrease) in fair value of accounts receivable acquired							1,800
Increase (decrease) in goodwill acquired, corresponding to accounts receivable remeasurement							1,800
Right-of-use assets, operating lease		7,601
Fair value of finite-lived intangible assets		94,000
Release of valuation allowance		3,500
Decipher Biosciences | Dr. Tina S. Nova, Ph.D.
Business Acquisition [Line Items]
Payments to board of directors members				$ 26,500
Decipher Biosciences | Dr. Robert S. Epstein, M.D., M.S.
Business Acquisition [Line Items]
Payments to board of directors members				$ 1,400
Decipher Biosciences | Off-Market Favorable Lease
Business Acquisition [Line Items]
Right-of-use assets, operating lease		1,800					1,800
Decipher Biosciences | Decipher product technology
Business Acquisition [Line Items]
Fair value of finite-lived intangible assets		$ 90,000
Estimated useful life		10 years
Decipher Biosciences | Decipher trade names
Business Acquisition [Line Items]
Fair value of finite-lived intangible assets		$ 4,000
Estimated useful life		5 years
Decipher Biosciences | Post-Combination Compensation Expense
Business Acquisition [Line Items]
Considerations paid in acquisition		$ 25,079
Incurred liabilities in acquisition		24,809
Cash considerations paid in acquisition		$ 270
NanoString
Business Acquisition [Line Items]
Considerations paid in acquisition			$ 40,000
Acquisition related contingent consideration			6,100				$ 8,400	$ 7,600
Goodwill			1,668
Fair value of finite-lived intangible assets			54,420
Additional cash to be paid			10,000
NanoString | Common Stock
Business Acquisition [Line Items]
Shares issued for purchase consideration for a business combination			$ 10,000